WAM
ABUS icon

Wealthspire Advisors (Maryland)’s Arbutus Biopharma ABUS Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-600
Closed -$3K – 1730
2015
Q4 		$3K Buy
+600
New +$3.29K ﹤0.01% 1440

Other funds holding ABUS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ABUS Position: Q1 2016 in Review

Wealthspire Advisors (Maryland) sold out of Arbutus Biopharma (ABUS) in Q1 2016, closing a stake of 600 shares — an estimated $3K sold.

Wealthspire Advisors (Maryland) first reported a position in ABUS in Q4 2015 and held it in 1 quarter. The position peaked at $3K in Q4 2015. 49 funds tracked by Wall St. Rank hold ABUS as of Q1 2016.

  • Wealthspire Advisors (Maryland) reported no remaining Arbutus Biopharma position as of Q1 2016 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 600 Arbutus Biopharma shares in Q1 2016, an estimated $3K.
  • Wealthspire Advisors (Maryland) first reported a position in Arbutus Biopharma in Q4 2015 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Arbutus Biopharma position peaked at $3K in Q4 2015.
  • 49 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2016.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q1 2016, filed 6 May 2016.